ARCH Venture Partners X, LLC bought $5.0M of Neumora Therapeutics (NMRA)
Executed Oct 27 2025, disclosed Oct 29 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 29 2025), the stock returned -11.9% (delay-adjusted); from the execution session (Oct 27 2025), -19.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
ARCH Venture Partners X, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales), most often in Neumora Therapeutics, Inc. (NMRA). Across 2 priced purchase filings, the average 21-session return was -13.6% from execution and -9.8% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of PRME (3,030,300 sh × $3.30, as filed), executed Aug 1 2025.
Healthcare · Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, ne…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→